Genelux (GNLX) Price to Sales (2023 - 2024)
Genelux (GNLX) posted Price to Sales of 21698.63 for Q1 2024, up 579.3% on a QoQ basis from 3194.28 in Q1 2023, and up 579.3% year-over-year from 3194.28 in Q2 2023.
Powered by 
Analysis
Genelux (GNLX) Price to Sales (2023 - 2024) Analysis & Trends
Genelux has reported Price to Sales for 2 years, with the latest figure at 21698.63 in Q1 2024.
- On a quarterly basis, Price to Sales rose 579.3% year-over-year to 21698.63 in Q1 2024; TTM through Dec 2024 was 10244.8, a 364.04% increase from a year earlier, with the FY2025 full-year figure at 20785.83, up 102.89% from the prior year.
- Price to Sales was 21698.63 for Q1 2024 at Genelux, up from 3194.28 in the prior quarter.
- The five-year high for Price to Sales was 21698.63 in Q1 2024, with the low at 3194.28 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - |